简体
简体中文
繁體中文

推特 TWTR

等待开盘 01-10 09:30:00 美东时间

53.70

0.000

0.00%

华盛通华盛通
立即下载
  • 最 高--
  • 今 开--
  • 成交量 0股
  • 最 低 --
  • 昨 收 53.70
  • 总市值 410.81亿
  • 52周最高 54.57
  • 市盈率 --
  • 换手率 0.00%
  • 52周最低 31.30
  • 委 比 0.00%
  • 总股本 7.65亿
  • 历史最高 80.75
  • 量 比 0
  • 振 幅 0.00%
  • 历史最低 13.725
  • 每 手 1
  • 风险率 0.00%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Praxis Precision Medicines granted 434 restricted stock units to three new non-executive employees under its 2024 Inducement Plan on January 2, 2026. These units vest annually over four years, contingent on continued employment. The plan is used to attract new hires with equity awards, aligning with Nasdaq Listing Rule 5635(c)(4).

    01-09 21:01

  • Clene Announces Registered Direct Offering of Over $28 Million

    Clene Inc. has completed a registered direct offering of over $28 million through three tranches, with new and existing investors including Boxer Capital Management, Coastlands Capital, and Vivo Capital. The first tranche of $6 million will fund operations into Q3 2026, the second tranche of $6.7 million is contingent on FDA NDA acceptance, and the third tranche of $15.6 million is contingent on FDA NDA approval. The financing aims to support CNM...

    01-09 13:30

  • Leslie’s, Inc. Appoints John Hartmann to Board of Directors

    Leslie's, Inc. has appointed John Hartmann as an independent director to its Board of Directors, effective January 7, 2026. With nearly 25 years of retail leadership experience, Hartmann has successfully led turnarounds for public and private companies across diverse industries. He joins as a Class III Director and will stand for election at the Company’s 2026 Annual Meeting. Hartmann’s addition expands the Board from eight to nine members. Lesli...

    01-08 13:30

  • Dogecoin Price Prediction: 2025 Maximum Drawdown Over 70%, 2026 DOGE Will Hit $1 Mark?

    Overall, Dogecoin's future remains highly uncertain. While it showed strong rebound momentum in early 2026, its price gains primarily depend on community consensus and market sentiment due to a lack of technical and ecosystem support. Should Bitcoin reach new highs again, DOGE might follow suit. How

    01-06 02:39

  • Mainz Biomed Provides Review of 2025 Highlights

    Mainz Biomed announced major achievements in 2025, including launching the eAArly DETECT 2 study for its next-generation colorectal cancer test and the feasibility study for a pancreatic cancer blood test showing 100% sensitivity and 95% specificity. ColoAlert®, their DNA-based CRC test, was registered in the UK and Switzerland, with partnerships expanding into South America and Switzerland. Additionally, the company secured public funding for it...

    01-05 14:15

  • Odysight.ai Inc. Announces Website Posting of CEO Letter to Shareholders

    Odysight.ai Inc., a leader in AI-powered visual sensing and predictive maintenance technologies, has made significant strides in 2025. The company successfully uplisted to NASDAQ (ODYS), raised $23.7 million, and secured over $14 million in contracts with strategic customers. Key achievements include fleet-level orders from the Israeli Air Force, collaborations with NASA, and expansion into industrial applications like railway monitoring, elevato...

    01-05 14:03

  • BridgeBio to Participate in the J.P. Morgan Healthcare Conference

    BridgeBio Pharma的联合创始人兼首席执行官Neil Kumar博士将在2026年1月12日参加第44届J.P. Morgan Healthcare Conference,并在会上发表演讲。投资者可通过BridgeBio官网观看直播或在活动后30天内观看回放。BridgeBio是一家专注于遗传病治疗方法的生物制药公司,成立于2015年,致力于通过基因医学的进步为患者带来变革性治疗方案。

    01-05 12:30

  • Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

    Halozyme Therapeutics and Skye Bioscience have entered into a global collaboration to develop and commercialize a subcutaneous formulation of nimacimab for obesity using Halozyme's ENHANZE® technology. Skye aims to evaluate higher doses of nimacimab and plans to initiate a Phase 2b trial in 2026. Halozyme will receive milestone payments and royalties on future sales.

    01-05 12:00

  • 推特、拼趣联合创始人推出社交新应用Tangle 欲破解社交媒体危害

      推特联合创始人比兹・斯通(Biz Stone)与 2010 年在线拼贴网站拼趣(Pinterest)联合创始人埃文・夏普(Evan Sharp),携手推出了...

    01-05 07:55

  • Blue Gold CEO Andrew Cavaghan Highlights Recent Milestones and Gold-Backed Stable Coin Market Opportunities in Newly Released Interview

    Blue Gold Limited announced the release of an interview with CEO Andrew Cavaghan, discussing the company's expanded platform supporting a gold-backed stablecoin, a consumer digital wallet, and a proprietary gold production and trading platform. The interview highlights the company's innovation in 2025 and strategic initiatives to scale market presence and enhance shareholder value. Blue Gold aims to deliver a vertically integrated gold fintech co...

    2025-12-30 20:30